- ICH GCP
- US Clinical Trials Registry
- Search trials
Clinical Trials on ALK or ROS1-positive NSCLC
Total 35038 results
-
PfizerFrench College of General Hospital Pneumologists (CPHG)CompletedNSCLC | Crizotinib | ALK Gene Rearrangement or ROS1 Gene RearrangementFrance
-
Addario Lung Cancer Medical InstituteCompletedALCMI-006: A Prospective Biospecimen Collection Study From Patients With ROS1-Fusion Positive TumorsROS1-fusion Positive TumorUnited States
-
Dr Joanne CHIURecruitingALK Gene Rearrangement Positive | EGF-R Positive Non-Small Cell Lung Cancer | EGFR Activating Mutation | Nsclc | ROS1 Gene Rearrangement | ROS1 Positive NSCLC - Reactive Oxygen Species 1 Positive Non-Small Cell Lung CancerHong Kong
-
PfizerTerminatedALK or ROS1-positive NSCLCChina
-
PfizerCompletedALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLCUnited States, Canada, Australia, Taiwan, Singapore, Japan, Korea, Republic of, Spain, Belgium, Switzerland, France, Germany, Hong Kong, Italy
-
TakedaCompletedCarcinoma, Advanced ALK+ or ROS1+Non-Small-Cell Lung, Neoplasm, Advanced ALK+ or ROS1+Solid TumorsSpain, Italy, Netherlands, France
-
Hoffmann-La RocheNo longer availableCancers With NTRK, ROS1, or ALK Gene FusionsUnited States
-
Jiangsu Simcere Pharmaceutical Co., Ltd.RecruitingAdvanced or Metastatic Solid Tumors With NTRK, ROS1 or ALK Gene FusionChina
-
Centre Francois BaclesseGFPCRecruitingALK Gene Rearrangement Positive | NSCLC Stage IV | NSCLC Stage IIIB | EGFR Gene Mutation | ROS1 Gene MutationFrance
-
Betta Pharmaceuticals Co., Ltd.Unknown
-
Sameek RoychowdhuryNational Cancer Institute (NCI)WithdrawnLocally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | ALK Gene Mutation | Metastatic Malignant Neoplasm in the Brain | Advanced Malignant Neoplasm | ALK Fusion Protein Expression | Metastatic Malignant Neoplasm in the Central Nervous System | ROS1 Gene Mutation | ALK Gene... and other conditionsUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.UnknownROS1-positive Non-Small Cell Lung Cancer (NSCLC)China
-
PfizerRecruitingEGFR Mutation-positive Inoperable or Reccrent NSCLCJapan
-
PfizerNo longer availableNon Small Cell Lung Cancer ALK Positive or ROS1 PositiveUnited States
-
Xuanzhu Biopharmaceutical Co., Ltd.Not yet recruiting
-
Novartis PharmaceuticalsTerminatedCeritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1 (SIGNATURE) (SIGNATURE)Tumors With Aberrations in ALK or ROS1United States
-
Arbeitsgemeinschaft medikamentoese TumortherapieRecruitingLung Cancer | NSCLC Stage IV | NSCLC, Stage III | SCLC, Extensive Stage | SCLC, Limited StageAustria
-
Jiangsu Aosaikang Pharmaceutical Co., Ltd.CompletedLocally Advanced or Metastatic NSCLCChina
-
AstraZenecaNo longer available
-
Jiangsu Aosaikang Pharmaceutical Co., Ltd.CompletedLocally Advanced or Metastatic NSCLCChina
-
Cancer Institute and Hospital, Chinese Academy...RecruitingUntreated Advanced NSCLC Patients | FISH Identified ALK Fusion Positive or NegativeChina
-
Yongchang ZhangRecruitingHER2 Insertion Mutation Positive Advanced NSCLCChina
-
CStone PharmaceuticalsPfizerActive, not recruitingAdvanced or Metastatic ROS1-Positive Non-Small Cell Lung CancerChina
-
AstraZenecaCompletedLocally Advanced or Metastatic EGFR(+) NSCLC PatientsChina
-
AstraZenecaCompletedLocally Advanced or Metastatic EGFR Mutated NSCLC.Taiwan
-
AstraZenecaCompletedCaucasian Patients With EGFR Mutation Positive Advanced NSCLCBulgaria, Italy, Poland, Spain, Turkey, United Kingdom, Romania, Norway, Hungary, Portugal, Greece, Switzerland, France
-
Betta Pharmaceuticals Co., Ltd.UnknownLung Cancer | ROS1 Gene RearrangementChina
-
MedSIRMedical University of ViennaNot yet recruitingNSCLC | Brain Metastases | ROS1 Gene Rearrangement
-
Centre Leon BerardRecruitingCancer | Cancer Metastatic | ALK Fusion Protein Expression | FGFR2 Gene Translocation | FGFR3 Gene Translocation | NTRK Family Gene Mutation | Gene Fusion | ROS1 Gene Translocation | NTRK Gene Fusion Overexpression | ATIC-ALK Fusion Protein Expression | BCR-FGFR1 Fusion Protein Expression | COL1A1-PDGFB Fusion... and other conditionsFrance, Denmark, Netherlands, Austria, Germany, Italy, United Kingdom, Czechia, Poland, Slovenia, Spain
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingLocally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | ROS1 Gene Rearrangement | Stage IIIB Lung Non-Small Cell Cancer AJCC v7 | Stage IV Lung Non-Small Cell Cancer AJCC v7 | ALK PositiveUnited States
-
Peking University Cancer Hospital & InstituteRecruitingHER2 Positive or Suspicious Positive TumorsChina
-
Monte Rosa Therapeutics, IncRecruitingNSCLC | SCLC | DLBCL | High Grade Neuroendocrine Cancer | L-MYC and N-MYC Amplified Solid Tumors | NSCLC With High or Low L-MYC or N-MYC ExpressionUnited States, Canada
-
National Cancer Centre, SingaporePfizerActive, not recruitingNSCLC Stage IV | NSCLC Stage IIIB | Recurrent NSCLC | NSCLC Stage IIIC | EGFR Positive Non-Small Cell Lung CancerKorea, Republic of, Hong Kong, Thailand, Singapore, Malaysia
-
AstraZenecaCompletedT790M Positive NSCLC PatientsChina
-
University of California, San FranciscoTerminatedALK Fusion Protein Expression | Stage III Cutaneous Melanoma | Stage IIIA Cutaneous Melanoma | Stage IIIB Cutaneous Melanoma | Stage IIIC Cutaneous Melanoma | Stage IV Cutaneous Melanoma | ROS1 Fusion Positive | BRAF wt Allele | Invasive Skin Melanoma | MET Fusion Gene Positive | NRAS wt Allele | NTRK1 Fusion... and other conditionsUnited States
-
Jiangsu Aosaikang Pharmaceutical Co., Ltd.RecruitingLocally Advanced or Metastatic NSCLCChina
-
Seoul National University HospitalSeoul National University Bundang Hospital; SMG-SNU Boramae Medical CenterActive, not recruitingLocally Advanced or Metastatic NSCLCKorea, Republic of
-
AstraZenecaCompletedLocally Advanced or Metastatic NSCLCKorea, Republic of, China, Japan
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingNSCLC | AML | SCLC | Ovarian Carcinoma | Malignant Tumor | ESCC | CRPC | MFChina
-
ETOP IBCSG Partners FoundationGlaxoSmithKline; Development LimitedRecruitingSCLC,Extensive Stage | SLFN11-positiveSwitzerland, France, Spain, Italy
-
AstraZenecaCompletedLocally Advanced or Metastatic EGFR T790M+ NSCLCCanada, Korea, Republic of, Taiwan
-
Peking University Cancer Hospital & InstituteBetta Pharmaceuticals Co., Ltd.RecruitingNSCLC Stage IV | NSCLC Stage IIIB | ALK PositiveChina
-
Maastricht Radiation OncologyAcademisch Ziekenhuis MaastrichtTerminatedNSCLC | Lung Cancer | SCLCNetherlands
-
Massachusetts General HospitalPfizer; Array BioPharmaRecruitingNSCLC | Lung Cancer | Relapsed Cancer | Resistant Cancer | MET Amplification | Anaplastic Lymphoma Kinase Gene Translocation | ROS1 RearrangementUnited States
-
University of Illinois at ChicagoWithdrawnKidney Transplant Rejection | Positive FCXM (T or B Cell Positive) | Positive CDC Cross-Match (B Cell Positive) | Kidney/Pancreas Transplant RejectionUnited States
-
Dana-Farber Cancer InstituteGenentech, Inc.TerminatedALK-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Non-small Cell Lung Cancer (NSCLC) | RET-positive Thyroid CancerUnited States
-
MediLink Therapeutics (Suzhou) Co., Ltd.RecruitingBreast Cancer | NSCLC | HNSCC | Locally Advanced or Metastatic Solid TumorsChina
-
Innovent Biologics (Suzhou) Co. Ltd.CompletedAdvanced or Metastatic NSCLCChina
-
Li Zhang, MDRecruitingThe Diagnosis Was ALK Positive NSCLC | Second Generation ALK-TKI is Resistant | Efficacy of Ensatinib in This Subset of PatientsChina